We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/1/2021 17:38 | Another inside day and consolidation above the breakout level | the stigologist | |
13/1/2021 16:30 | Good inside day | the stigologist | |
12/1/2021 21:40 | RENE Nice breakout | the stigologist | |
12/1/2021 17:07 | Someone very keen to get on board before this train leaves the station | the stigologist | |
12/1/2021 17:02 | Another great day. It's looking exciting. | small crow | |
12/1/2021 14:10 | Real momentum building, could easily mirror what happened in April/May 2019. | katsy | |
12/1/2021 10:39 | Worth sharing the link in that TS! This is good to read: The hRPC update was part of a broader trading statement delivered ahead of ReNeuron’s annual meeting in which it reiterated its belief it will see increasing industry interest in its exosomes programme translate into further collaborations. It has already signed two research evaluation agreements with companies interested in exploring the potential of the technology. “In addition, we expect to be able to sign further collaboration agreements, currently under negotiation, in the near term,” the company added. Let's hope the expectations translate to facts! PS. Note the article is from Sept 2020, but still worth repeating. Must be getting nearer! | lauders | |
12/1/2021 10:26 | Brilliant must read thread on #RENE this RENE now potentially a world leading company in a whole new biotechnology platform technology area Exosomes (Recent Goldman Sachs IPO CDAK Codiak went from $150m to $600m) RENE EV of £40m doesn't do justice to the potential for positive newsflow on this exciting prospect No wonder Professor Sir Chris Evans invested £1m in recent fundraising | the stigologist | |
12/1/2021 09:09 | Breaking out | the stigologist | |
08/1/2021 09:50 | I dare say that someone who co-founded and then sold an $800M company is not exactly living paycheck to paycheck. He may well have invested although I imagine there would be complications regarding potential insider information so this would need to be handled carefully. | whatno | |
08/1/2021 08:24 | Is this traded on multiple exchanges? | katsy | |
07/1/2021 15:49 | Why would further collaborations be a huge catalyst? The previous 3 werent. I think you may have to wait for the end of the proof of concepts and subsequent licence agreements | luffness | |
07/1/2021 15:37 | He may have built it but the sale might involve large contingent back ended payouts so who knows how much he has to invest Prof Evans put £1m in | the stigologist | |
07/1/2021 15:34 | if that was the case then bg3 he will buy a big chunk ?? | martinfrench | |
07/1/2021 14:34 | I've been a holder here for a while, just listened to the analyst call. Lots of little snippets a non-scientist such as myself can take away. Re prof Maclaren, built and sold Nightstar for $830m, saw the results here and asked to be involved. He wouldn't be doing that if he didn't see something to get excited about ! | bg23 | |
07/1/2021 14:15 | It's clear from the call that Prof Maclaren is going to be guiding the RP clinical trial going forwards. He has already shaped it by proposing further endpoints that RENE have now included. These will significantly improve the chances of approval by the FDA. Let's not forget that he was the driver behind Nightstar that was sold for $800M.and that a single shot of Luxturna has been approved by NICE @£600k! | onceaday | |
07/1/2021 13:57 | That slide on Value Inflection Points makes it pretty clear we should expect Pharma collabs like err imminently... January 2021 right ? Which is going to be a huge catalyst if they pull it off Next week's Biotech Showcase and JPM Healthcare Conference perfect time to deliver news as well | the stigologist | |
07/1/2021 09:21 | Nice stealth breakout of medium term downtrend going on | the stigologist | |
06/1/2021 15:48 | All quite positive. They really need to ensure they meet the target of all 9 RP patients treated by early Q2. They have had plenty of time to prepare for the trial. Exosomes have real potential for near term value creation. They are working with 3 third party therapeutics and I was pleased.to hear they have another two in the pipeline and are only constrained by RENE's resources. If just a few of these bear fruit the value coming through could be huge. | onceaday | |
06/1/2021 15:34 | Just finished listening to this morning's presentation. Worth a listen. | pdt | |
06/1/2021 10:47 | Well, someone’s taking a optimistic view! | rayrac |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions